Mesenbio

Mesenbio is a biotechnology startup founded in 2021 in the United Kingdom. The company's focus lies in utilizing mesenchymal stem cells (MSCs) to produce therapeutically meaningful extracellular vesicles (EVs). Mesenbio's innovation has garnered attention and secured a significant £1.40M investment in a Seed Round on 09 January 2024 from NG Bio and DSW Ventures. Spun out from the Genever lab with over 20 years of expertise in cell biology and regenerative medicine at the University of York, Mesenbio's approach addresses the limitations of current therapies by providing an endless source of therapeutically active EVs with improved batch consistency. Their focus on musculoskeletal regeneration, particularly targeting osteoarthritis, presents a compelling solution to a significant socioeconomic burden, considering the aging populations and the lack of disease-modifying drugs. The company's agile and versatile MSC-EV production platform positions them as a potential game-changer in the biotechnology space. With a promising technology and a strong investment backing, Mesenbio exhibits the potential to bring about significant advancements in the field of regenerative medicine and therapeutic EV production.